Cooper Companies, Inc. (The) (NYSE:COO) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Tuesday. The brokerage currently has a $265.00 target price on the medical device company’s stock. Zacks Investment Research‘s target price indicates a potential upside of 13.26% from the stock’s current price.

According to Zacks, “The Cooper Companies had an impressive run on the bourse over the last six months. The company ended third-quarter fiscal 2017 on a solid note, beating the Zacks Consensus Estimate on both lines. The Cooper Companies has always seen impressive results at its CooperVision business segment. Notably, the segment banks on the platforms of MyDay, Clariti and Biofinity silicone hydrogel lenses. The CooperSurgical segment also delivered strong sales in the quarter. The company provided strong guidance for fiscal 2017. However, the dampening outlook for the CooperSurgical segment indicates looming concerns. Furthermore, intensifying competition in the contact lens space will continue to increase pricing pressure. Cooper Companies has completed the acquisition of Procornea in the recent past. This added a leading ortho-k technology to Cooper Company’s lens portfolio and marked its foray in the emerging myopia controlled markets.”

Several other research firms have also recently commented on COO. Robert W. Baird reissued a “buy” rating and issued a $273.00 target price (up from $267.00) on shares of Cooper Companies, Inc. (The) in a research note on Tuesday, September 12th. Jefferies Group LLC set a $250.00 target price on Cooper Companies, Inc. (The) and gave the company a “buy” rating in a research note on Thursday, August 17th. Oppenheimer Holdings, Inc. reissued a “hold” rating and issued a $250.00 target price on shares of Cooper Companies, Inc. (The) in a research note on Tuesday, September 12th. Cleveland Research reissued a “buy” rating on shares of Cooper Companies, Inc. (The) in a research note on Tuesday, August 22nd. Finally, J P Morgan Chase & Co reissued a “hold” rating and issued a $235.00 target price on shares of Cooper Companies, Inc. (The) in a research note on Tuesday, September 12th. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $261.11.

Shares of Cooper Companies, Inc. (COO) traded down 1.12% during mid-day trading on Tuesday, hitting $233.97. The stock had a trading volume of 344,697 shares. The firm’s 50-day moving average price is $242.36 and its 200 day moving average price is $230.16. Cooper Companies, Inc. has a 12-month low of $158.73 and a 12-month high of $256.39. The stock has a market cap of $11.45 billion, a price-to-earnings ratio of 33.55 and a beta of 0.54.

Cooper Companies, Inc. (The) (NYSE:COO) last released its earnings results on Thursday, August 31st. The medical device company reported $2.64 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.58 by $0.06. The company had revenue of $556.00 million during the quarter, compared to analysts’ expectations of $552.32 million. Cooper Companies, Inc. (The) had a return on equity of 16.00% and a net margin of 16.45%. The business’s revenue for the quarter was up 8.0% on a year-over-year basis. During the same period last year, the firm earned $2.30 EPS. Equities analysts forecast that Cooper Companies, Inc. will post $9.73 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was originally published by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2017/10/10/zacks-investment-research-upgrades-cooper-companies-inc-the-coo-to-buy.html.

In other news, Director Gary S. Petersmeyer sold 3,977 shares of the firm’s stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $244.94, for a total value of $974,126.38. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Paul L. Remmell sold 9,294 shares of the firm’s stock in a transaction on Friday, July 14th. The stock was sold at an average price of $248.46, for a total value of $2,309,187.24. Following the completion of the transaction, the chief executive officer now owns 6,186 shares in the company, valued at $1,536,973.56. The disclosure for this sale can be found here. 1.60% of the stock is owned by company insiders.

Large investors have recently bought and sold shares of the company. Schwab Charles Investment Management Inc. boosted its position in shares of Cooper Companies, Inc. (The) by 5.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 244,686 shares of the medical device company’s stock worth $58,583,000 after purchasing an additional 13,004 shares during the last quarter. Scout Investments Inc. boosted its position in shares of Cooper Companies, Inc. (The) by 29.3% in the 2nd quarter. Scout Investments Inc. now owns 116,320 shares of the medical device company’s stock worth $27,849,000 after purchasing an additional 26,370 shares during the last quarter. Keybank National Association OH boosted its position in shares of Cooper Companies, Inc. (The) by 18.4% in the 2nd quarter. Keybank National Association OH now owns 8,631 shares of the medical device company’s stock worth $2,066,000 after purchasing an additional 1,343 shares during the last quarter. Amalgamated Bank boosted its position in shares of Cooper Companies, Inc. (The) by 27.0% in the 2nd quarter. Amalgamated Bank now owns 9,764 shares of the medical device company’s stock worth $2,338,000 after purchasing an additional 2,073 shares during the last quarter. Finally, Oak Ridge Investments LLC boosted its position in shares of Cooper Companies, Inc. (The) by 36.0% in the 2nd quarter. Oak Ridge Investments LLC now owns 19,294 shares of the medical device company’s stock worth $4,619,000 after purchasing an additional 5,110 shares during the last quarter. Institutional investors and hedge funds own 95.78% of the company’s stock.

About Cooper Companies, Inc. (The)

The Cooper Companies, Inc is a global medical device company. The Company operates through two business units: CooperVision, Inc and CooperSurgical, Inc CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses.

Get a free copy of the Zacks research report on Cooper Companies, Inc. (The) (COO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Cooper Companies, Inc. (The) (NYSE:COO)

Receive News & Ratings for Cooper Companies Inc. (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies Inc. (The) and related companies with MarketBeat.com's FREE daily email newsletter.